kc-1438
KRAS encodes KRas proto-oncogene, GTPase and is also known as NS. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region.
| Catalog Number | kc-1438 |
|---|---|
| Cell Line Name | NIH/3T3-KRAS-WT Cell Line |
| NCBI/UniProt Accession Number | NM_033360.3 |
| Host Cell Line | NIH/3T3 |
| Description | NIH/3T3-KRAS-WT is a stable engineered cell line expressing human KRAS-WT |
| Quantity | One vial of frozen cells (≥2×10⁶ cells/vial) |
| Stability | Stable in culture over a minimum of 10 passages |
| Application | Drug screening and biological assays |
| Freezing Medium | 70% DMEM+20% FBS+10% DMSO |
| Propagation Medium | DMEM+10%FBS+1μg/mL Puromycin |
| Selection Marker | Puromycin |
| Morphology | Epithelial |
| Subculture | Split at a ratio of 1:4–1:6 every 2–3 days |
| Incubation | 37 °C with 5% CO₂ |
| Storage | Liquid nitrogen immediately upon receiving |
| Doubling Time | Estimated 19–36 hours |
| Mycoplasma Status | Negative |
| In Vivo Validation | NA |